$Ardelyx (ARDX.US)$ Citigroup raised the price target on Ard...
$Ardelyx(ARDX.US$
Citigroup raised the price target on Ardelyx Inc (NASDAQ:ARDX) to $13 from $7, with a Buy rating unchanged.The update follows the Company's plans to launch Ibsrela (tenapanor) for irritable bowel syndrome with constipation (IBS-C) independently in Q2 2022. Analyst Yigal Nochomovitz added IBS-C revenues in the U.S. back to his model and noted that his estimates are in line with management's guidance for $500M at peak, which Nochomovitz sees coming in 2029. He also argues that the Ibsrela launch partially shifts the focus off the formal dispute resolution process with the FDA for hyperphosphatemia and gives Ardelyx another near-term catalyst.Ladenburg upgraded Ardelyx to Buy from Neutral with a $6 price target. Analyst Matthew Kaplan believes the product for IBS-C could generate greater than $400 million in revenues by 2026. Kaplan also notes that Ardelyx announced plans to file a Formal Dispute Resolution Request during Q4 to appeal the CRL for tenapanor for hyperphosphatemia. He looks forward to the filing of the FDRR and more detail on the path forward for this indication.
Citigroup raised the price target on Ardelyx Inc (NASDAQ:ARDX) to $13 from $7, with a Buy rating unchanged.The update follows the Company's plans to launch Ibsrela (tenapanor) for irritable bowel syndrome with constipation (IBS-C) independently in Q2 2022. Analyst Yigal Nochomovitz added IBS-C revenues in the U.S. back to his model and noted that his estimates are in line with management's guidance for $500M at peak, which Nochomovitz sees coming in 2029. He also argues that the Ibsrela launch partially shifts the focus off the formal dispute resolution process with the FDA for hyperphosphatemia and gives Ardelyx another near-term catalyst.Ladenburg upgraded Ardelyx to Buy from Neutral with a $6 price target. Analyst Matthew Kaplan believes the product for IBS-C could generate greater than $400 million in revenues by 2026. Kaplan also notes that Ardelyx announced plans to file a Formal Dispute Resolution Request during Q4 to appeal the CRL for tenapanor for hyperphosphatemia. He looks forward to the filing of the FDRR and more detail on the path forward for this indication.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
train your mind to stay calm in every situation
革命尚未成功，同志仍需努力
647Followers
31Following
1049Visitors
Follow
Matthew D : Fair value 13 consensus by 7 analysts, current price 1.4 with 90milliom shares owed by shorts, if we hold and buy more, this will be more epic than gamestop
single grad Matthew D : hey how do you feel about $Ardelyx (ARDX.US)$ now?